Technical Analysis for AMAM - Ambrx Biopharma Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Downtrend | Bearish | 105.43% | |
Bullish Engulfing | Bullish | 105.43% | |
Pocket Pivot | Bullish Swing Setup | 105.43% | |
20 DMA Resistance | Bearish | 109.58% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 109.58% | |
Inside Day | Range Contraction | 109.58% | |
20 DMA Resistance | Bearish | 106.03% | |
Doji - Bullish? | Reversal | 106.03% | |
Fell Below 20 DMA | Bearish | 106.79% | |
Down 3 Days in a Row | Weakness | 106.79% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 04/23/2024
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Health Sciences Pharmacy Cancer Immunotherapy Antibody Drug Conjugate Oncology Therapies Beigene
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Health Sciences Pharmacy Cancer Immunotherapy Antibody Drug Conjugate Oncology Therapies Beigene
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.15 |
52 Week Low | 6.56 |
Average Volume | 1,997,117 |
200-Day Moving Average | 15.99 |
50-Day Moving Average | 25.33 |
20-Day Moving Average | 27.86 |
10-Day Moving Average | 27.95 |
Average True Range | 0.18 |
RSI (14) | 82.17 |
ADX | 55.72 |
+DI | 43.61 |
-DI | 13.57 |
Chandelier Exit (Long, 3 ATRs) | 27.48 |
Chandelier Exit (Short, 3 ATRs) | 28.06 |
Upper Bollinger Bands | 28.05 |
Lower Bollinger Band | 27.66 |
Percent B (%b) | 0.86 |
BandWidth | 1.40 |
MACD Line | 0.66 |
MACD Signal Line | 0.90 |
MACD Histogram | -0.2404 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 28.03 | ||||
Resistance 3 (R3) | 28.03 | 28.01 | 28.03 | ||
Resistance 2 (R2) | 28.01 | 28.01 | 28.02 | 28.02 | |
Resistance 1 (R1) | 28.01 | 28.00 | 28.01 | 28.01 | 28.02 |
Pivot Point | 27.99 | 27.99 | 28.00 | 28.00 | 27.99 |
Support 1 (S1) | 27.99 | 27.99 | 27.99 | 27.99 | 27.98 |
Support 2 (S2) | 27.97 | 27.98 | 27.98 | 27.98 | |
Support 3 (S3) | 27.97 | 27.97 | 27.98 | ||
Support 4 (S4) | 27.97 |